“In this setting, patients are polymorphic, and the disease is heterogeneous,” Dr. Sharma explained. “We must generate hypotheses from the clinical data sets…take those data back to the laboratory, and in the appropriate immunocompetent model, test our hypotheses to understand deeper mechanisms that can lead to the next generation of clinical studies.”

#immunotherapy

https://ascopost.com/issues/december-25-2022/from-the-clinic-to-the-lab-overcoming-resistance-to-immune-checkpoint-therapy/